PMID- 8700555
OWN - NLM
STAT- MEDLINE
DCOM- 19960904
LR  - 20220408
IS  - 0950-9232 (Print)
IS  - 0950-9232 (Linking)
VI  - 13
IP  - 1
DP  - 1996 Jul 4
TI  - Detection and quantitation of HER-2/neu gene amplification in human breast cancer 
      archival material using fluorescence in situ hybridization.
PG  - 63-72
AB  - Amplification and overexpression of the HER-2/neu gene occurs in 25-30% of human 
      breast cancers. This genetic alteration is associated with a poor clinical 
      prognosis in women with either node negative or node positive breast cancers. The 
      initial studies testing this association were somewhat controversial and this 
      controversy was due in large part to significant heterogeneity in both the 
      methods and/or reagents used in testing archival material for the presence of the 
      alteration. These methods included a number of solid matrix blotting techniques 
      for DNA, RNA and protein as well as immunohistochemistry. Fluorescence in situ 
      hybridization (FISH) represents the newest methodologic approach for testing for 
      this genetic alteration. In this study, FISH is compared to Southern, Northern 
      and Western blot analyses as well as immunohistochemistry in a large cohort of 
      archival human breast cancer specimens. FISH was found to be superior to all 
      other methodologies tested in assessing formalin fixed, paraffin embedded 
      material for HER-2/neu amplification. The results from this study also confirm 
      that overexpression of HER-2/neu rarely occurs in the absence of gene 
      amplification in breast cancer (approximately 3% of cases). This method of 
      analysis is rapid, reproducible and extremely reliable in detecting presence of 
      HER-2/neu gene amplification and should have clinical utility.
FAU - Pauletti, G
AU  - Pauletti G
AD  - Department of Medicine, University of California, Los Angeles, School of 
      Medicine, Los Angeles, California 90095, USA.
FAU - Godolphin, W
AU  - Godolphin W
FAU - Press, M F
AU  - Press MF
FAU - Slamon, D J
AU  - Slamon DJ
LA  - eng
GR  - CA36827/CA/NCI NIH HHS/United States
GR  - CA48780/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Oncogene
JT  - Oncogene
JID - 8711562
RN  - 0 (DNA, Neoplasm)
RN  - 0 (Fixatives)
RN  - 0 (Neoplasm Proteins)
RN  - 1HG84L3525 (Formaldehyde)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Blotting, Northern
MH  - Blotting, Southern
MH  - Blotting, Western
MH  - Breast Neoplasms/*genetics/pathology
MH  - DNA, Neoplasm/*genetics
MH  - Female
MH  - Fixatives
MH  - Formaldehyde
MH  - *Gene Amplification
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Neoplasm Proteins/*genetics
MH  - Paraffin Embedding
MH  - Receptor, ErbB-2/*genetics
MH  - Reproducibility of Results
MH  - Tissue Fixation
EDAT- 1996/07/04 00:00
MHDA- 1996/07/04 00:01
CRDT- 1996/07/04 00:00
PHST- 1996/07/04 00:00 [pubmed]
PHST- 1996/07/04 00:01 [medline]
PHST- 1996/07/04 00:00 [entrez]
PST - ppublish
SO  - Oncogene. 1996 Jul 4;13(1):63-72.